AbbVie Halts Another Trial With I-Mab Antibody, Slashes Deal Size

 
• By Dexter Jie Yan

AbbVie is to terminate the clinical development of lemzoparlimab for myelodysplastic syndrome and acute myeloid leukemia and will also reduce the size of its 2020 deal with originator I-Mab by $445m, in the latest blow to the Chinese firm.

CD47 discontinuation
AbbVie has now terminated two early global trials with I-Mab's lemzoparlimab • Source: Shutterstock

More from Clinical Trials

More from R&D